SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Stock Information for SCYNEXIS Inc.
Loading
Please wait while we load your information from QuoteMedia.